Merck & Co. deny New England Journal of Medicine’s claims it withheld negative information about arthritis medication Vioxx
Friday, December 9th, 2005.
An editorial appearing Thursday December 9, 2005 in The New England Journal of Medicine called into question the information provided by Merck for a key study about cardiovascular events caused by the arthritis drug Vioxx. The study called into question was published in November of 2000 for the VIGOR (Vioxx Gastrointestinal Outcomes Research) Study Group. The prestigious medical journal requested a correction to the information, the lack of which amounted to an “understatement” of the risks.
Vioxx Study & Information Withheld:
- Expression of Concern: Bombardier et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” N Engl J Med 2000;343:1520-8. (PDF). Thursday, December 8, 2005. The New England Journal of Medicine.
- Bombardier, et al. for The VIGOR Study Group. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. Friday, November 23, 2000. The New England Journal of Medicine.
- Merck responds to medical publication. Friday, December 9, 2005. CNNMoney.com
- Merck & Co., Inc. Response to an Editorial Posted on the New England Journal of Medicine Web Site. (Press Release). Thursday, December 8, 2005. Merck.com.
You can follow any responses to this entry through the RSS 2.0 feed.
Responses are currently closed, but you can trackback from your own site.
